INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
- TRADE NAME: Rexulti (Otsuka)
- INDICATIONS: Schizophrenia, major depressive disorder (with antidepressants)
- CLASS: Antipsychotic, Antipsychotic, atypical
- HALF-LIFE: 86–91 hours
- FDA APPROVAL DATE: 07/10/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Strong or moderate CYP2D6 inhibitors, Strong or moderate CYP3A4 inducers or inhibitors - PREGNANCY: Neonatal risk in third trimester exposure
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/22/2024
